BioPharmSignal logoBioPharmSignal

Biotech News

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Acumen Pharmaceuticals (ABOS)Acumen PharmaceuticalsEarnings

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today reported financial results for the third quarter of 2026 and provided a business update.

Related news

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

XERSXeris Pharmaceuticals2026-11-05 12:00 EST

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

XERSXeris Pharmaceuticals2026-10-22 12:00 EST

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

SUPNSupernus2026-10-19 12:30 EST

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

TNXPTonix Pharmaceuticals2026-10-26 11:00 EST

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026

TSHATaysha Gene Therapies2026-11-05 13:00 EST

Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12

CGTXCognition Therapeutics2026-11-02 12:30 EST

Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026

PRAXPraxis Precision Medicines2026-10-27 20:01 EST

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation

NBIXNeurocrine Biosciences2026-10-12 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results

View all latest news

Acumen Pharmaceuticals

Alzheimer’s Disease Antibody Company Acumen Pharmaceuticals develops therapies targeting soluble amyloid-beta oligomers, which are believed to contribute directly to synaptic dysfunction in Alzheimer’s disease. Sabirnetug Sabirnetug is a monoclonal antibody designed to selectively bind toxic amyloid-beta oligomers while limiting...

Recent company news

ABOSAcumen Pharmaceuticals2026-10-30 11:00 EST

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

ABOSAcumen Pharmaceuticals2026-10-26 11:00 EST

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

ABOSAcumen Pharmaceuticals2026-10-22 11:30 EST

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ABOSAcumen Pharmaceuticals2026-10-19 20:00 EST

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

ABOSAcumen Pharmaceuticals2026-09-10 20:00 EST

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

Stock data

Close
0.21 USD
Market cap
171.18M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States